CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 63 enrolled
Drug / intervention
Oxytocin +1 moredrug
Likely dose
Oxytocin 40 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02742532
NCT02742532Phase 2Completed
CompareCT.gov

Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress

Jennifer Mitchell·interventional·Posted Apr 19, 2016·Updated Oct 19, 2020

In Brief

A Phase 2 clinical trial evaluating Oxytocin and Placebo for Alcohol Use Disorder and 3 related conditions. Completed, enrolled 63 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether oxytocin will decrease craving to use drugs/alcohol and stress reactivity following exposure to laboratory-induced stress among Active Duty Service Members with a dual diagnosis of alcohol/substance use disorder (ASUD) and post-traumatic anxiety.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Use Disorder, Stress Disorders, Post-Traumatic, Anxiety Disorders, Substance Use Disorders
CountriesUnited States
CollaboratorsUnited States Naval Medical Center, San Diego, United States Department of Defense, Congressionally Directed Medical Research Programs, Eisenhower Army Medical Center

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 19, 2016
Enrollment StartApr 20, 2017
Primary CompletionJul 1, 2019
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 10.2 years ago

Interventions

Oxytocindrug

Intranasal oxytocin 40 IU

Placebodrug

Intranasal saline solution